Clinical Signs and Symptoms {#Sec1}
===========================

Signs and symptoms of (Table [26.1](#Tab1){ref-type="table"}):MeningitisEncephalitisCerebral dysfunctions (delirium, lethargy, confusion, stupor, coma)SeizuresFocal neurologic deficitsTable 26.1Neurologic signs and syndromes related to affected regionsLocalizationSyndromeNeurologic signsMeninges• Meningitis• Headache• Vomiting• Photophobia• Focal neurologic deficits• Alterations in consciousnessBrain parenchyma diffuse• Encephalitis• Alterations in consciousness• Seizures• Multifocal neurologic deficitsBrain parenchyma focal• Encephalitis• Cerebritis• Focal neurologic deficits• SeizuresBrain stem and posterior cranial fossa• Brain stem encephalitis• Cerebellitis• Opto- and pupillomotor disturbances• Nuclear cranial nerve lesions• Dysarthria• Bilateral pyramidal tract signs• Alterations in consciousness• Breathing insufficiency• Vegetative signsSpinal cord• Myelitis• Paraplegia• Brown Séquard syndromeArteries• Arteritis• Sudden focal neurologic deficitVeins• Septic venous sinus thrombosis• Headache• Seizures• Raised brain pressure• Focal neurologic deficits

Classification of Viruses {#Sec2}
=========================

Classification of viruses based on their nuclei acid into (Tables [26.2](#Tab2){ref-type="table"} and [26.3](#Tab3){ref-type="table"}):DNA virusesRNA virusesTable 26.2Subdivision of virusesDNA virusesEnveloped• Pox• Herpes• HepadnaNaked capsid• Polyoma, Papilloma, Adeno• ParvoRNA viruses+RNA• Naked capsid: Picorna, Calici• Enveloped: Toga, Flavi, Corona--RNA• Enveloped: Rhabdo, Filo, Orthomyxo, Paramyxo, Bunya, Arena±RNA• Double capsid: Reo+RNA via DNA• Enveloped: RetroTable 26.3A detailed subdivision of virusesViral genomeFamily name of virusFamily membersDNADouble-strandedHerpesviridae• HSV-1• HSV-2• Varicella-zoster virus• Cytomegalovirus• Epstein-Barr virus• Human herpesvirus 6• Human herpesvirus 7• Human herpesvirus 8• Herpes simiaeAdenoviridae• AdenovirusPapovaviridae• JC virus• Simian virus 40Single-strandedParvoviridae• Parvovirus B19RNADouble-strandedReoviridae• Coltivirus• SeadornavirusSingle-stranded sense non-segmentedRetroviridae• Deltaretrovirus• LentivirusCoronaviridae• CoronavirusTogaviridae• AlphavirusFlaviviridae• FlavivirusPicornaviridae• EnterovirusSingle-stranded antisense segmentedBunyaviridae• Orthobunyavirus• PhlebovirusArenaviridae• ArenavirusSingle-stranded antisense non-segmentedOrthomyxoviridae• Influenza virusesParamyxoviridae• Henipavirus• Morbilivirus• RubulavirusRhabdoviridae• Rabies• BornaFiloviridae• Ebola

The diseases caused by viruses are listed in Table [26.4](#Tab4){ref-type="table"} while brain diseases caused by viruses are depicted in Tables [26.5](#Tab5){ref-type="table"} and [26.6](#Tab6){ref-type="table"}.Table 26.4List of viruses and related diseases of virusesViral familyVirusDiseaseDNAPapillomavirus• Warts• Condylomas• Cervical cancerPolyomaviridaeBK virus• Renal diseaseJC virus• Progressive multifocal leukoencephalopathyAdenoviridae• Respiratory disease• MeningoencephalitisAlphaherpesvirinaeHerpesvirus 1• EncephalitisHerpesvirus 2• EncephalitisVaricella-zoster virus• EncephalitisGammaherpesvirinaeEpstein-Barr virus• EncephalitisBetaherpesvirinaeCytomegalovirus• EncephalitisPoxviruses• SmallpoxParvoviruses• Erythema infectiosumPicornavirusesEnterovirus• Encephalitis• Meningitis• Poliovirus infections (polyomyelitis, paralytic polio)Hepatovirus• HepatitisRNAPicornaviridaePoliovirus• Poliomyelitis• Postpolio syndromeEnterovirusesCardiovirus genusEncephalomyocarditis virusArbovirusesTogaviridae, alphavirus genus• Eastern equine encephalitis• Western equine encephalitis• Venezuelan equine encephalitisFlaviviridae• Japanese encephalitis• St. Louis Encephalitis• Russian spring-summer encephalitis• Central European encephalitis• Kyasanur forest disease• Murray valley encephalitis• RocioBunyaviridae• La Crosse encephalitis• Snowshoe hare virus• California encephalitis• Jamestown canyon encephalitisReoviridae• Colorado tick feverParamyxovirusesMeasles virus• MeaslesParainfluenza virus• Limited respiratory tract infectionMumps virus• MumpsOrthomyxovirusesInfluenza A and B viruses• InfluenzaRhabdovirusesRhabdovirus• RabiesRetrovirusesOncovirinae (HTLV)• Tropical spastic paraparesisLentivirinae (HIV)• Acquired immune deficiency syndrome (AIDS)Table 26.5Viral infections of the brain and their causative viral agentsEncephalitis• HSV-1• Toga, Flavi, Bunya encephalitis viruses• Picornaviruses• Arboencephalitis virus• Varicella-zoster virus• Rabies virus• Polioviruses• Coxsackie A and B virusesMeningitis• HSV-2• Picornaviruses• Mumps virus• Enteroviruses -- Echoviruses -- Coxsackie virus -- Poliovirus• AdenovirusesParalysis• Poliovirus• Enterovirus 70 and 71• Coxsackie A7 virusPostinfectious encephalitis (immune mediated)• Measles virus• Mumps virus• Rubella virus• Varicella-zoster virus• Influenza virusOther• JC virus-progressive multifocal leukoencephalopathy (PML)• Human Immunodeficiency Virus (HIV)• Human T-cell lymphotropic virus 1 (HTLV-1) (tropical spastic paraparesis)• Measles variant (subacute sclerosing panencephalitis)Table 26.6Acute and chronic viral infection affecting the brainAcute viral infection• Aseptic meningitis• Polyomyelitis• Neonatal enteroviral encephalitis• Herpesvirus infections -- Herpes simplex virus infection -- Atypical herpes simplex encephalitis -- Chronic granulomatous herpes simplex encephalitis -- Necrotizing myelopathy -- Neonatal HSV encephalitis -- Varicella-zoster virus (ZVZ) infection -- Epstein-Barr virus (EBV) infection -- Cytomegalovirus (CMV) infection -- Human herpesviruses 6 and 7• Adenovirus• Paramyxoviruses -- Mumps virus -- Measles• Rubella encephalitis• Rabies• Arbovirus infectionsChromic and subacute viral infections• Chronic enteroviral encephalomyelitis• Subacute measles encephalitis• Subacute sclerosing panencephalitis (SSPE)• Progressive rubella panencephalitis• Progressive multifocal leukoencephalopathy (PML)• Human T-cell leukemia/lymphotropic virus-1 (HTLV-1)• Human immunodeficiency virus (HIV)• Rasmussen encephalitis

Epidemiology {#Sec100}
============

Incidence1.5--7 cases/100,000 inhabitants/year, excluding epidemicsTrue incidence of these infections is difficult to determine becauseMany cases are unreported.The diagnosis may not be considered.A specific viral etiology is never confirmed. Age Incidenceall ages possibleCMV: congenital, adulthoodHIV: adulthood Sex Incidencedependent on virusHIV: predominantly malesCMV: equal distribution LocalizationBrain, any regionTemporal lobe for HSV

Neuroimaging Findings {#Sec101}
=====================

General Imaging FindingsViral CNS infections can either lead to meningitis or (meningo-)encephalitis.Imaging of viral encephalitis often nonspecific---like focal or diffuse edema (acute infection) or focal atrophy (chronic infection)---except HSV encephalitis showing an almost pathognomonic involvement of limbic system.Location depends on causative agent. CT Non-Contrast-EnhancedMeningitis: NormalEncephalitis: Hypodense edema, loss of gray-white matter differentiation, chronic infection may cause brain atrophy CT Contrast-EnhancedMeningitis: Meningeal enhancement often missingEncephalitis: Enhancement possible MRI-T2Encephalitis: Hyperintensity of involved brain areas MRI-FLAIREncephalitis: Hyperintensity of involved brain areas MRI-T1Encephalitis: Hypointense edema with loss of gray-white matter differentiation MRI-T1 Contrast-EnhancedMeningitis: Weak meningeal enhancementEncephalitis: Variable enhancement MRI-T2∗/SWIEncephalitis: Hemorrhages (HSV, VZV, Japanese encephalitis) MR-Diffusion ImagingEncephalitis: Diffusion restriction common

Typical MR imaging patterns of specific viral encephalitides are listed in Table [26.7](#Tab7){ref-type="table"}.Table 26.7Typical MR imaging patterns of specific viral encephalitidesHSV• Limbic system and temporal lobe• Often hemorrhages and enhancementCMV• Periventricular white matter, subependymal enhancement• Calcifications in perinatal CMVEBV• Symmetric involvement of basal ganglia, thalami, cortex, or brain stem• Rarely EBV-cerebellitisVZV• Multifocal cortical areas• Hemorrhagic infarctions possibleHIV• Brain atrophy• Symmetric confluent white matter lesions (periventricular, basal ganglia, centrum semiovale, brain stem, cerebellum),• No enhancementRabies virus• Diffuse involvement of basal ganglia, thalami, periventricular white matter, brain stem, and hippocampiTBEV (Tick-borne encephalitis virus)• MRI and CT often normal• Rarely lesions in thalamus, cerebellum, caudate nucleus, and brain stemJC Virus (PML)• Confluent subcortical white matter lesions, predominantly in parieto-occipital lobes• U-fibers involvedJEV (Japanese encephalitis virus)• Bilateral symmetric lesions in thalami, basal ganglia, and midbrainEnteroviruses• Posterior medulla oblongata and pons, dentate nuclei, and midbrainNuclear Medicine Imaging FindingsIn HIV-infected patientsReduced brain perfusion SPECT and reduced FDG-PET uptake of cortical structures (medial frontal, temporoparietal) are described.FDG shows diffuse hypermetabolism in subcortical and deep white matter, basal ganglia, and thalami in some cases.In herpes simplex encephalitisHMPAO showed increased uptake followed by a decrease in tracer uptake in the recovery phase and ECD decreased uptake of the affected temporal lobe (most likely due to disturbed membrane and intracellular metabolism).FDG-PET shows hippocampal hypermetabolism in the acute phase of herpes simplex encephalitis followed by hypometabolism after 3--9 months, but it is reported, that hypometabolism can persist for years.Studies with various imaging agents are performed to assess different pathologic steps in neuroinflammation.

Neuropathology Findings {#Sec102}
=======================

Macroscopic FeaturesNo discernible lesionHemorrhagic lesionNecrotic lesion Microscopic FeaturesSee specific subchaptersPerivascular lymphocytic cuffingGliomesenchymal nodulesMultinucleated giant cellsLarge cells with inclusion bodiesReactive astrogliosisLeukoencephalopathies Immunohistochemical Staining CharacteristicsAntibodies directed against a specific virus or part of the virusHIV: p24, gp41 Differential DiagnosisNecrosis of malignant tumors or metastasesNecrosis from other infectious agents

Molecular Neuropathology {#Sec3}
========================

Properties of viruses, i.e., DNA versus RNA viruses (Table [26.8](#Tab8){ref-type="table"})Entry into the bodyViral receptors (Table [26.9](#Tab9){ref-type="table"})Delivery of the virus to the target tissueInteraction of virus with target tissueStability of virus in the bodyAbility to establish viremiaAbility to spread through the reticuloendothelial systemCytopathogenesisFailed infection (abortive infection)Cell death (lytic infection)Replication without cell death (persistent infection)Presence of virus without production but with potential for reactivation (latent-recurrent infection)Host responsesAntigen-nonspecific (innate) host defensesAntigen-specific immune responsesViral mechanisms of escape to immune responsesImmunopathologyInterferonT-cell responses: cell killing, inflammationAntibody: complement, antibody-dependent cellular cytotoxicity, immune complexesOther inflammatory responsesVirus production in a tissue with release of the virus to other people (contagion)Transmission of viruses dependsOn source of the virus (tissue site of viral replication and secretion)Ability of the virus to endure hazards and barriers of the environment Table 26.8Properties of DNA viruses and RNA virusesDNA virusesRNA viruses• DNA is not transient or labile.• Many DAN viruses establish persistent infections.• DNA genomes reside in the nucleus.• Viral DNA resembles host DNA for transcription and replication.• Viral genes must interact with host transcriptional machinery.• Viral gene transcription is temporally regulated.• Early genes encode DNA-binding proteins and enzymes.• Late genes encode structural and other proteins.• DNA polymerases require a primer to replicate the viral genome.• The larger DNA viruses encode means and promote efficient replication of their genome.• RNA is labile and transient.• Most RNA viruses replicate in the cytoplasm.• Cells cannot replicate RNA. RNA viruses must encode an RNA-dependent RNA polymerase.• The genome structure determines the mechanism of transcription and replication.• RNA viruses are prone to mutation.• The genome structure and polarity determine how viral messenger RNA is generated and proteins are processed.• RNA viruses, except (+) RNA genome, must carry polymerases• All (−) RNA viruses are enveloped. Table 26.9Viral receptorsVirusTarget cellReceptorEpstein-Barr virusB-cellC3d complement receptor CR2 (CD21)Human immunodeficiency virusHelper T-cellCD4 molecule and chemokine co-receptorRhinovirusEpithelial cellsICAM-1 (immunoglobulin superfamily protein)PoliovirusEpithelial cellsImmunoglobulin superfamily proteinHerpes simplex virusMany cellsHerpesvirus entry mediator (HVEM), nectin 1Rabies virusNeuronAcetylcholine receptor, NCAMInfluenza A virusEpithelial cellsSialic acidB19 parvovirusErythroid precursorsErythrocyte P antigen (globoside)

Treatment and Prognosis {#Sec4}
=======================

TreatmentAntiviral drugs aim at altering:Virion disruptionAttachmentPenetration and uncoatingRNA synthesisGenome replicationProtein synthesisVirion assembly and release

Antiviral drugs include:Nucleoside analogsAcyclovirGanciclovirNonnucleoside polymerase inhibitorsProtease inhibitorsImmunomudulatorsBiologic Behavior--Prognosis--Prognostic FactorsAge of infectionCongenitalNature of diseaseTarget tissuePortal of entry of virusAccess of virus to target tissueTissue tropism of virusPermissiveness of cells for viral replicationPathogenic activity (strain)Severity of diseaseCytopathic ability of virusImmune statusCompetence of the immune systemPrior immunity to the virusImmunopathologyProgression of viral diseaseAcquisitionActivation of innate protectionsIncubation periodTarget tissueHost responsesContagionResolution or persistent infection/chronic disease

Unspecified Nodular Encephalitis {#Sec5}
================================

The only histological finding in unspecified nodular encephalitis is the presence of gliomesenchymal nodules (GMN) (Fig. [26.1a--d](#Fig1){ref-type="fig"}). The finding is indicative of a viral infection.Fig. 26.1Unspecified nodular encephalitis (**a**--**d**) (Stain: H&E)

GMN are:composed of microglia, macrophages, and reactive astrocytesfound in the gray and white matterabsence of multinucleated giant cells (MGC) or large cells containing inclusion bodies

The differential diagnosis for GMN includesHIV-1 encephalopathy/leukoencephalopathyCytomegalovirus encephalitisThe nodules are very suspicious to contain CMV when further serial sectioning is performed.Toxoplasma gondii encephalitis

Complete clarification and identification of an infectious agent is sometimes not possible.

RNA Viruses: Human Immunodeficiency Virus (HIV)-1 {#Sec6}
=================================================

Human immunodeficiency virus (HIV)-1 infection is a serious health problem worldwide as 33 million adults and 2 million children are infected with HIV-1. Despite preventive efforts, the epidemic continues to spread rapidly and the socioeconomic consequences of the neurologic dysfunction caused by HIV-1 infection are of enormous proportions. Most of the affected patients live in developing countries, where antiretroviral medications are not available.

HIV-viruses (1, 2) areRetroviruses, lentivirinae subfamilyRoughly spheric, enveloped, RNA virusesDiameter of 80--120 nmRNA-dependent DNA polymeraseEncode accessory genes*Gag*: group-specific antigen: core and capsid proteins*Int*: integrase*Pol*: polymerase: reverse transcriptase, protease, integrase*Pro*: protease*Env*: envelope: glycoproteins*Tat*: transactivation of viral and cellular genes*Rev*: regulation of RNA splicing and promotion of export to cytoplasm*Nef*: decreases cell surface CD4, facilitates T-cell activation, progression to AIDS*Vif*: virus infectivity, promotion of assembly, blocks a cellular antiviral protein*Vpu*: facilitates virion assembly and release, induces degradation of CD4*Vpr*: transport of complementary DNA to nucleus, arresting of cell growth, replication in macrophagesLTR: promoter, enhancer elements

Following involvement of the lung (75--85%), the brain is the second most frequently affected organ (60--80%) in HIV-1 infection.

Neurological signs and symptoms are seen:In about 50% of HIV-1-infected patients.In approximately 10% of the cases, they are the first presentation of the disease.

The term "AIDS dementia complex (ADC)" was coined in 1986 (Navia et al. [@CR100], [@CR101]) to describe impaired memory and concentration, psychomotor slowing and behavioral disturbances in 65% of patients, and has been attributed mainly to subcortical damage of AIDS brains (subcortical dementia). The name ADC was later changed into HIV-1-associated cognitive and motor complex with HIV-1-associated dementia complex (motor)/(behavior) (HAD) and HIV-1-associated myelopathy as its severe manifestations and HIV-1-associated minor cognitive/motor disorder as its mild manifestation (Force [@CR43]).

Classification of HIV-associated neurocognitive disorders (HAND) (Antinori et al. [@CR7])Asymptomatic neurocognitive impairment (ANI)No evidence of pre-existing cause. Cognitive impairment must be attributable to HIV and no other etiology (e.g., dementia, delirium).The cognitive impairment does not interfere with activities of daily living.Involves at least two cognitive areas (memory, attention, language, processing speed, sensory perceptual, motor skills) documented by performance of \>1 standard deviation below the mean of standardized neuropsychological testing.30% prevalence in combination antiretroviral therapies (CART)-treated HIV+ individuals.Mild neurocognitive disorder (MND)No evidence of pre-existing cause. Cognitive impairment must be attributable to HIV and no.Other etiology (e.g., dementia, delirium).At least mild interference in \>1 activities of daily living including mental acuity, inefficiency at work, homemaking or social functioning.20--30% prevalence in combination antiretroviral therapies (CART)-treated HIV+ individuals.HIV-associated dementia (HAD)No evidence of another pre-existing cause for dementia (i.e., CNS infections, CNS neoplasm, cerebrovascular disease).Marked interference in activities of daily living.Marked cognitive impairment involving at least two cognitive domains by performance of \>2 standard deviation below the mean of standardized neuropsychological tests, especially in learning of new information, slowed information processing and defective attention or concentration.2--8% prevalence in combination antiretroviral therapies (CART)-treated HIV+ individuals.

Despite the introduction of antiretroviral therapies with a greater life expectancy of HIV-1-infected individuals, epidemiologic data suggest that involvement of the brain in AIDS patients continues to be a frequent autopsy finding.

Neuropathological examinations show in up to 95% of the brains changes that may be due to:primary effect of HIV-1probable effect of HIV-1opportunistic agentsneoplasias

The neuropathological changes seen in the brains (Table [26.10](#Tab10){ref-type="table"}) and peripheral nerve and skeletal muscle (Table [26.11](#Tab11){ref-type="table"}) of HIV-1-infected patients are manifold.Table 26.10The neuropathological changes seen in the brains of HIV-1-infected patientsChanges primarily due to HIV-1• HIV-1 encephalitis (HIVE)• HIV-1 leukoencephalopathy (HIVL)• HIV-1 myelitis• Lymphocytic meningitis (LM)• Meningeal lymphocytic infiltration (MLI)• Perivascular lymphocytic infiltration (PLI)Changes probably due to HIV-1• Vacuolar myelopathy• Vacuolar leukoencephalopathyOpportunistic infections---viruses• Cytomegalovirus infection (CMV)• Progressive multifocal leukoencephalopathy (PML)• Herpes simplex virus 1• Herpes simplex virus 2• Herpes zoster• HTLV-1• Varicella-zoster virusOpportunistic infections---parasites• Toxoplasma gondii• Acanthamoeba• Leptomyxid amoeba• Trypanosoma cruzi• StrongyloidesOpportunistic infections---fungi• Aspergillus fumigatus• *Candida albicans*• *Cryptococcus neoformans*• Others including: Histoplasma, Phycomyces, Coccidioides, Blastomyces, Acremonium, CladosporiumOpportunistic infections---bacteria• Pyogenic: *Escherichia coli*, Listeria, Staphylococcus, Salmonella• Mycobacterial: *Mycobacterium tuberculosis*, *Mycobacterium avium* intracellulare• Spirochetal: Treponema pallidum• Filamentous: Nocardia• Miscellaneous: Whipple's diseaseNeoplasias• Lymphoma (primary and secondary)• Kaposi sarcomaTable 26.11The changes occurring in the peripheral nervous system and in skeletal muscles of HIV-1-infected patientsPeripheral nervous system• Acute inflammatory demyelinating (poly) (radiculo) neuropathy• Chronic inflammatory demyelinating (poly) (radiculo) neuropathy• Axonal neuropathy• Ganglionitis, ganglioradiculitis, (poly) (radiculo) neuritis• necrotizing vasculitis, vasculitic neuropathySkeletal muscle• (Poly) myositis• Necrotizing myopathy• Nemaline rod myopathy• Vesicular myopathy, mitochondrial myopathy• Necrotizing vasculitis

HIV-1 Encephalitis (HIVE) {#Sec7}
-------------------------

Since HIV-1 is rarely the cause of focal macroscopic lesions even in severely infected patients, systematic sampling of specimens for histological examination is required. If focal lesions are present, they are almost always due to opportunistic infections, cerebrovascular complications, or neoplasms.

### Neuroimaging Findings {#Sec104}

General Imaging FeaturesBrain atrophy and symmetric confluent white matter lesions (periventricular, basal ganglia, centrum semiovale, brain stem, cerebellum), no enhancement CT Non-Contrast-EnhancedBrain atrophySymmetric confluent white matter hypodensities CT Contrast-EnhancedNo enhancement MRI-T2/FLAIR (Fig. [26.2a--d](#Fig2){ref-type="fig"})Focal white matter hyperintensitiesDiffuse white matter hyperintensities MRI-T1 (Fig. [26.2e, f](#Fig2){ref-type="fig"})Lesions usually not seen MRI-T1 Contrast-Enhanced (Fig. [26.2g, h](#Fig2){ref-type="fig"})No enhancement MRI-DWI (Fig. [26.2i, j](#Fig2){ref-type="fig"})No restricted diffusion. Fig. 26.2HIV encephalopathy, T2 (**a**, **b**), FLAIR (**c**, **d**), T1 (**e**, **f**), T1 contrast (**g**, **h**), DWI (**i**, **j**)

### Microscopical Findings {#Sec8}

HIV-1 encephalitis is characterized by (Fig. [26.3a--j](#Fig3){ref-type="fig"})Multiple disseminated foci composed of microglia, macrophages, and multinucleated giant cells (MGCs). The foci are predominantly located in the cortex, deep gray matter, and the white matter.The multinucleated giant cells (MGC) are the hallmark for HIV-1 encephalitis.They contain up to 20 round or elongated and basophilic nuclei which are usually arranged at the periphery of the cell.The cytoplasm is eosinophilic and appears densely stained in the center and vacuolated at the periphery.The cells are of monocyte/histiocyte lineage which includes microglia and macrophages.They are derived from HIV-1-mediated fusion of infected microglia and macrophages.The nucleic acids of HIV proteins have been demonstrated to be located in their cytoplasm.In their absence, the presence of HIV-antigen or HIV nucleic acids has to be demonstrated either by immunohistochemistry, i.e., gp41 and p24 (Fig. [26.3j](#Fig3){ref-type="fig"}) or by in situ hybridization.HIVE usually occurs in the later stages of the AIDS infection.The electron microscopical analysis revealed retroviral particles either free in the cytoplasm or in cytoplasmic cisternae.Microglia/macrophages and MGC are capable of HIV synthesis and, thus, constitute the major reservoir and vehicle for the spread of the virus.Synonyms previously used: giant cell encephalitis, multifocal giant cell encephalitis, multinucleated cell encephalitis, subacute encephalitisFig. 26.3HIV-1-encephalitis: multinucleated giant cells (**a**--**i**) (**a**--**h**: Stain: H&E; **i**: Stain: cresyl violet). HIV-1 antigen shown in a small gliomesenchymal nodule (**j**: stain: immunohistochemistry for p24)

There is no strong correlation between HIVE and the clinical stages of the HAD.

Despite the introduction of HAART with a greater life expectancy of infected individuals, epidemiologic data suggest that the prevalence of HIVE is on the rise.

HIV-1 Leukoencephalopathy (HIVL) {#Sec9}
--------------------------------

HIV-1 leukoencephalopathy is chararcterized by (Fig. [26.4a--j](#Fig4){ref-type="fig"})diffuse damage to the white matter includingmyelin lossreactive astrogliosismacrophagesmultinucleated giant cellsMyelin pallor is usually found around the gliomesenchymal nodule containing the MGC.Little or no inflammatory infiltrates are seen.In the absence of multinucleated giant cells, the presence of HIV-antigen or HIV nucleic acids has to be demonstrated either by immunohistochemistry or by in situ hybridization.Axonal damage can be demonstrated with immunohistochemistry for β-amyloid precursor protein.HIVL usually occur in the later stages of the AIDS infection.Synonyms previously used: progressive diffuse leukoencephalopathyFig. 26.4HIV-leukoencephalopathy: presence of multinucleated giant cells in the white matter (**a**, **b**: H&E, **c**: LFB, **d**: cresyl violet) and myelin pallor loss (**e**--**j**)

Lymphocytic Meningitis (LM) and Perivascular Lymphocytic Infiltration (PLI) {#Sec10}
---------------------------------------------------------------------------

*Lymphocytic meningitis (LM)* is characterized by (Fig. [26.5a--f](#Fig5){ref-type="fig"})Significant lymphocytic infiltrates in the leptomeninges.No opportunistic pathogens are encountered in the meninges.Fig. 26.5Meningeal lymphocytic infiltrates (**a**--**f**: Stain: H&E). Perivascular lymphocytic infiltrates (**g**--**j**: Stain: H&E)

*Perivascular lymphocytic infiltration (PLI)* is characterized by (Fig. [26.5g--j](#Fig5){ref-type="fig"})Significant lymphocytic infiltrates in the perivascular spaces of the brain tissue.No opportunistic pathogens are encountered in the perivascular brain tissue.

It seems that lymphocytic infiltrates in the leptomeninges and in the perivascular spaces of the brain tissue constitute changes occurring in the early stages of the HIV-1 infection.

Vacuolar Myelopathy (VM) and Vacuolar Leukoencephalopathy (VL) {#Sec11}
--------------------------------------------------------------

*Vacuolar myelopathy* is characterized by (Fig. [26.6a--f](#Fig6){ref-type="fig"})Numerous vacuolar myelin swellings.Macrophages in multiple areas of the spinal cord.Predominant involvement of the dorsolateral spinal tracts.Some macrophages may be found in the vacuoles.Might not be specific for HIV-1 since they can occur in the absence of HIV.The axon is at first unaffected, but it is damaged in the later stages of the disease.VM might not be specific for HIV-1Fig. 26.6Spinal cord showing vacuolar myelopathy of the dorsal tracts (**a**--**d**: stain LFB, **e**: stain H&E, **f**: stain: Woelcke's myelin stain)

*Vacuolar leukoencephalopathy* is characterized byNumerous vacuolar myelin swellings in the central white matter.Some macrophages may be found in the vacuoles.VL is a rare condition.

Neuropathological Changes in Early Stages of HIV-1 Infection {#Sec12}
------------------------------------------------------------

Brain changes in HIV-1 seropositive, non-AIDS cases include:Cerebral vasculitis was significantly more frequent and marked in HIV seropositive cases and was often associated with lymphocytic meningitis (Gray et al. [@CR54]).Granular ependymitis, myelin pallor with reactive astrocytosis, and microglial proliferation were also more frequent and more severe in HIV seropositive cases. Immunohistochemistry was negative for HIV-antigens. Highly expressed cytokines (tumor necrosis factor-α, interleukin (IL)-1,4,6) (Gray et al. [@CR54]).Perivascular lymphocytic infiltrates (PLI) as well as lymphocytic infiltrates in the meninges (MLI) were found in 62.8% of the cases. PLI alone was seen in 61% of the cases, MLI alone in 43% of the cases, and the combination of PLI and MLI in 34% of the cases (Weis et al., unpublished data).

Neuropathological Changes in HIV-1-Infected Children {#Sec13}
----------------------------------------------------

Children born to HIV-1-infected mothers are in 10--40% of the cases also infected by the virus (Kozlowski et al. [@CR76]). These children develop symptoms before the age of 2 years.About 30% of the HIV-1 children develop opportunistic infection or HIV-1 encephalopathy within the first year of life.Brain growth is impaired leading to intellectual deficiency.The gross-anatomical analysis shows brains which are too small for the age.Sometimes atrophic gyri may be noted.Microcephaly and/or brain atrophy is present.The most common findings in brains of HIV-1-infected children areMineralization of predominantly small vessels found in 95% of the case.Myelin pallor and gliosis are the noted changes of the white matter that occur in 78% of the cases.MGC are seen in 62% of HIV-1-infected children.Opportunistic infections are comparatively uncommon.

Therapy: HAART Effects and Therapy-Induced Immune Restitution Inflammatory Syndrome (IRIS) {#Sec14}
------------------------------------------------------------------------------------------

In 1995/1996, highly active antiretroviral therapies (HAART) were introduced which combinenucleoside reverse transcriptase inhibitors (NRTI)specifically inhibit the viral reverse transcriptase enzyme necessary for DNA chain elongation of the virusprotease inhibitors (PI)prevent the production of active virus by interfering with the cleavage of proteins necessary for viral assembly

Effects of the therapy results in:The frequency of HIV-1-related CNS diseases has been reduced throughthe reduction of both viral load in the bloodthe reduced continuous penetration of virus into the brain (Tardieu [@CR1320])HIV-positive patients live longer.The median survivalfollowing AIDS increased from 19.6 months in 1993--1995 to 39.6 months for those diagnosed in 1996--2000following ADC increased from 11.9 months in 1993--1995 to 48.2 in 1996--2000.The proportion of patients with AIDS dementia complex (ADC) increased from 5.2% in 1993--1995 to 6.8% in 1996--2000.

Larger cohort autopsy studies of HIV-infected patients over longer time periods suggest that, despite the beneficial effects of modern antiretroviral combination therapy, involvement of the brain in AIDS subjects continues to be a frequent autopsy finding (Gray et al. [@CR53], [@CR55]; Jellinger et al. [@CR66]; Langford et al. [@CR78]) (Tables [26.12](#Tab12){ref-type="table"} and [26.13](#Tab13){ref-type="table"}).Table 26.12Review of 1597 consecutive autopsies of HIV-1-positive patients performed between 1984 and 2000, and division into four time periods on the basis of the therapeutic regimens available (Vago et al. ([@CR138]) reproduced with kind permission by Wolters Kluver Health)YearTherapy*n*HIV-E/LOpportunistic infections1984--1987No therapy11953.840.31988--1994Monotherapy (zidovudine)111632.246.81995--1996Dual combination therapy with nucleoside reverse transcriptase inhibitors25617.942.61997--2000Triple combination therapy including two NRTIs and at least one protease inhibitor or non-NRTI10615.142.5Table 26.13Frequencies for various neuropathological changes in pre-HAART era compared to HAART eraAuthor (year)*n*HIVEHIVLCMVPMLTOXOLYMGray et al. ([@CR53])Pre-HAART4037.5Nip20.05.047.52.5Gray et al. ([@CR55])^a^HAART2317.4Nip8.717.413.013.0Jellinger et al. ([@CR66])Pre-HAART3528.54.318.57.122.28.5HAART988.05.011.05.08.06.0Langford ([@CR78])Pre-HAART6225.8Nip16.16.46.419.3HAART8943.8Nip16.85.60.08.9*n* sample size, *HIVE* HIV-1 encephalitis, *HIVL* HIV-1 leukoencephalopathy, *CMV* cytomegalovirus encephalitis, *PML* progressive multifocal leukoencephalopathy, *TOXO* toxoplasma gondii encephalitis, *LYM* primary non-Hodgkin lymphoma^a^Frequencies for pre-HAART could not be calculated due to lack of original data in their paper

Immune reconstitution inflammatory syndrome (IRIS) is a syndrome that emerges when the immune system recovers after an immune deficiency state (Table [26.14](#Tab14){ref-type="table"}) (Nelson et al. [@CR102]; Chahroudi and Silvestri [@CR28]; McCarthy and Nath [@CR94]). IRIS is an adverse clinical manifestation that occurs in HIV-infected individuals treated successfully with ART and consists of a paradoxical deterioration of clinical status despite improved CD4-T-cell counts and immunologic conditions.Table 26.14Clinical manifestations of IRIS in patients with HIV-1 infection on cART modified after McCarthy and Nath ([@CR94]) reproduced with kind permission by Springer NatureInfectionTypical clinical manifestationsAtypical clinical manifestationsHIV encephalitis• Asymptomatic• Mild cognitive decline• Fulminant decline in mental status over days with brain swelling and inflammationPML with JCV• Subacute focal neurologic deficits• Focal areas of contrast enhancement and swellingVaricella-zoster virus• Shingles• CNS vasculitis• Strokes without skin rashCytomegalovirus• Retinitis• Cerebritis• VasculitisEpstein-Barr virus• CNS lymphoma• Optic neuropathyTuberculosis• Meningitis• Cerebral infarcts• Subarachnoid hemorrhageCryptococcus• Meningitis• Enhancing mass lesions in posterior fossaCandida• Meningitis• Vasculitis with strokes

A new variant of HIVE has emerged in the era of HAART as a severe leukoencephalopathy with significant perivascular infiltration of macrophages and lymphocytes which is assumed to be the result of an exaggerated response from a newly reconstituted immune system (Persidsky and Gendelman [@CR108]).

Neuropathological examination revealedSevere inflammatory lesions.Demyelinating lesions with marked intraparenchymal and perivascular infiltration by macrophages and T-lymphocytes.In some cases, abundant viral proliferation was identified by immunocytochemistry or in situ hybridization, but in others the infectious agent could only be detected using PCR.T-lymphocytes were predominantly CD8(+).In those cases with the more favorable course, inflammation was less severe with marked macrophage activation and a number of CD4(+) lymphocytes.In the lethal cases, inflammation was severe and mostly composed of CD8(+) cytotoxic lymphocytes.

The Sequalae of HIV-1 Infection of the Nervous System {#Sec15}
-----------------------------------------------------

In summary, the following changes of the brain have been described to be due to the HIV-1 infection:Brain weight (Weis, unpublished data)no changesBrain edema (Weis, unpublished data)no significant differenceGross-anatomy (Gelman and Guinto [@CR47])No apparent macroscopical signs of atrophy are seen by bare visual inspection.Cerebrospinal fluid (CSF) space greater than two standard deviations above the mean of the age-matched control subjects.CSF spaces expanded most in the frontal and temporal lobe.Ventricular system (Weis, unpublished data) (Gelman and Guinto [@CR47])Widening of the lateral ventricles.Ventricular spaces expanded more than the sulcal spaces.Volume of brain regions (Oster et al. [@CR106]; Subbiah et al. [@CR130]; Weis et al. [@CR147])No significant changes in volume, surface area, mean cortical thickness.Reduction of the mean volume of the neocortex.Reduction in volume of the central brain nuclei.Reduction in volume of the internal capsule.Mean neocortical thickness was reduced by 12%.There were no differences in white matter volumes between groups.The mean volume of the white matter was reduced by 13%.Mean ventricular volume was increased by 55%.There were no significant differences between the AIDS groups with and without HIV-associated dementia.Neuronal numberCerebral cortex (Ketzler et al. [@CR73]; Weis et al. [@CR146])Loss of neurons in different cortical regions.Neuronal loss is not be correlated with development of dementing symptoms and of HIV-specific neuropathology.Basal gangliadecrease in neuronal density (21%) in the putamen especially in those cases with HIV-1 encephalitis (Everall et al. [@CR41]).Cerebellumsignificant reduction of the volume density, the numerical density of neurons as well as neuronal size was apparent in the cerebellar dentate nucleus and in both inferior olivary nuclei (Abe et al. [@CR1])Substantia nigraThe total number of neuronal cell bodies was 25% lower in AIDS than in age-matched controls although the volume density of neuronal melanin did not differ from that of controls because the percentage of pigmented cell bodies was higher and the cell bodies were more fully packed with melanin in AIDS (Reyes et al. [@CR111]).The size of total neurons (pigmented and non-pigmented neurons) and of pigmented neurons was significantly reduced in all investigated nuclei (antero-medial, antero-intermediolateral, posterolateral, and posteromedial nuclei) of HIV-1-infected brains.Furthermore, the nigral neuronal loss showed no relationship with immunohistochemical detection of HIV-1 antigens (gp41, p24).The numerical density of non-pigmented large neurons (type II neurons) was significantly increased in HIV-1-infected brains suggesting that (1) non-pigmented, dopaminergic neurons or non-pigmented, non-dopaminergic neurons might be relatively preserved in the SN of HIV-1 infection, or (2) that pigmented dopaminergic neurons loose their melanin pigments during the early stages of degeneration, which also might be responsible for functional deterioration (Itoh et al. [@CR64]).Neuronal size (Weis et al. [@CR146])no changes in perikaryal sizeSynapses (Wiley et al. [@CR153])Loss of synapses as shown by a decrease in the immunoreactivity against synaptophysinDendrites (Masliah et al. [@CR92], [@CR93])Apical dendritesdilated, vacuolated, and tortuousdecreased length and branchingBasal and oblique dendritesshow the same alterations, but to a lesser extentSome dendrites present lacunae and filopodia consistent with remodeling.40--60% decrease in spine density throughout the entire length of dendrites.Fewer spines on neurons; 55% fewer on the first segment, 40% fewer on the second, 45% fewer on the third, 60% fewer on the fourth, and 65% fewer in the fifth segment.Aberrant spines in regions of abnormal second-order dendritic branches.Nerve fibersWhite matterLoss of nerve fibers in the white matterCorpus callosum (Wohlschlaeger et al. [@CR156])Reduced thickness of the myelin sheath of nerve fibers in the corpus callosum.Calculation of the *g*-ratio revealed a relative increase in size of the axon and a relative decrease in the myelin sheath thickness.The data indicated a reduction in the size of nerve fibers and axons as well as thinner myelin sheaths, whereas in other callosal regions axons and myelin sheaths were swollen and enlarged.These changes were observed in regions which are unaffected, as revealed by light-microscopic analysis of sections stained for myelin.Optic nerve (Tenhula et al. [@CR133])Degeneration was often severe and was scattered throughout all of the AIDS-affected optic nerves.Despite the approximate 40% loss of axons in the AIDS-affected optic nerves, the mean axonal population was markedly lower than the mean obtained from normal optic nerves (880,000 vs. 1,507,000).The mean axonal diameters were not markedly different, that the changes may not only be secondary to damage at the retina, but may reflect an AIDS-associated primary optic neuropathy.Astroglia (Weis et al. [@CR145]; Ciardi et al. [@CR30])no change in the number of all astrocytes (i.e., GFAP-positive and GFAP-negative astrocytes)reduction of the number of GFAP-negative cellsincrease of reactive GFAP-positive astrocytesnot correlated with loss of nerve cellsincrease in nuclear size of GFAP-negative and GFAP-positive astrocytesincrease of the size of the cytoplasm of GFAP-positive astrogliano correlation between the neuronal loss and the pattern of reactive astrocytosisOligodendroglia (Esiri et al. [@CR40])significant increase in the number of oligodendrocytes associated with mild degree of myelin damagedecrease of oligodendrocytes in severely affected areasslight increase in immunoreactivity for the enzymes carbonic anhydrase II and 2′,3′-cyclic nucleotide 3′-phosphodiesterasesignificant increase in the numerical density of transferrin-immunopositive cells of the white matteran initial reactive hyperplasia which may represent an attempt to repair myelin damage taking place already early during the HIV-1 infectionMicroglia/macrophages (Weis et al. [@CR148])Activated in gray and white matter of all brain regions.Activation pattern is not correlated with the presence of HIV-antigen gp41 and p24 in the brain tissue.Vessels (Buttner et al. [@CR24]; Weis et al. [@CR149])Significant increase in the diameter of cortical vesselsIncrease of the volume fraction, surface area of vesselsNo changes in length density indicating no changes in the number of vesselsIncrease of the numerical density of vessels in the gray matterNo changes in the numerical density of vessels in the white matterThinning of the basal lamina as seen by electron microscopyReduced immunoreactivity for collagen IV and laminin (thinning of the basal lamina)Vascular endothelial cell (Buttner et al. [@CR24]; Weis et al. [@CR149])loss of glycoproteins SBA, UEA-I, and WGA of the endothelial cell membranedecrease of immunoreactivity for von Willebrand factor (Factor VIII)no significant differences RCA-INo changes in size at the electron microscopic levelCapillaries (Weis and Haug [@CR144])region-specific changesincreased capillary profile areaincreased capillary diameterdecreased basal lamina thicknessincreased endothelial cell sizeunchanged pericyte size

Pathogenetic Mechanisms {#Sec16}
-----------------------

### Mode of Entrance of HIV-1 to the Brain {#Sec17}

HIV-1 enters the CNS byHIV-1 is passively carried by T-lymphocytes and monocytes---the "Trojan Horse" hypothesis.Cell-free HIV-1 particles may also penetrate brain microvascular endothelial cells.After crossing the BBB into the CNS, macrophages spread productive HIV-1 infection to neighboring microglia.Microglia serve asa reservoir for persistent viral infection and replicationa vehicle for viral dissemination throughout the braina major source of neurotoxic products that affect glial function, the blood--brain barrier and neuronal function, and finally lead to cell deathMicroglia and monocyte-derived macrophages express both the CD4 and chemokine coreceptors (CCR5, CXCR4), the prerequisite for HIV-1 to enter a cell.The potential role of the cerebrospinal fluid or the choroid plexus as a means for HIV-1 entry in the brain is still unclear.At the time of primary HIV-1 infection, an acute aseptic meningitis or encephalitis indicates central nervous system invasion.The point in time when the migration of HIV-1-infected lymphocytes into the brain takes place is not known. It has been shown that, at the time of seroconversion, HIV-1 can be detected in the CSF; this is the time when, clinically, a subacute meningitis develops, thus, suggesting that HIV-1 enters the CNS at a very early stage of the disease.Opportunistic infectious agents or drugs of abuse disturbing the BBB may further attract more HIV-1-infected T-lymphocytes and macrophages into the brain.

### Target Cells of HIV-1 Infection {#Sec18}

The cells in the brain identified to contain HIV-1 are:MicrogliaMacrophagesMultinucleated giant cellsAstrocytes (possibly)Endothelial cells (possibly)Oligodendrocytes (possibly)Mechanisms of Brain LesionsThe development of brain lesions due to opportunistic infections and lymphomas might be explained by the lack of a competent immunologic defense system.One might assume that the changes described in Sect. [26.5.8](#Sec14){ref-type="sec"} might result by direct infection with HIV-1.However, it has been shown that neither neurons, nor astrocytes nor endothelial cells are infected with HIV-1.Thus, these changes more probably result from indirect toxic factors that are produced either by infected multinucleated giant cells or by activated microglia.Neuronal dropout occurs in brain regionsThat are free from any neuropathological changes.Neuronal damage in AIDS was, at least, partly due to apoptosis.No correlation was found between the presence and severity of neuronal loss or of neuronal apoptosis and a history of cognitive disorders.No correlation between the presence of HIV-1 proteins and neuronal loss.The reactive astrogliosis was not correlated with the loss of nerve cells, indicating that this reaction pattern is rather a response to toxic factors secreted into the brain tissue.The number of activated microglia/macrophages is significantly increased in all brain regions. This activation of microglia is not correlated with the presence of HIV-1 antigen in the brain tissue. Activated microglia/macrophages, rather than MGCs, most probably secrete toxic factors.The neurotoxicity associated with HIV-1 infection is mediated, in part, throughcytokinesarachidonic acid metabolitesproduced during cell-to-cell interactions between HIV-1-infected brain macrophages and astrocytesPathobiological events underlying the neurodegenerative processes in HIV-1-associated dementia are believed to begin with productive infection of monocytes/macrophages by HIV-1.Peripheral activation causes the differentiation of macrophages to produce a variety of immune products that lead to the upregulation of adhesion molecules on brain microvascular endothelial cells and the expression of adhesins on the monocyte-macrophage cell surface.After penetration of the BBB, the differentiated brain macrophages and microglia can be vehicles for viral dissemination throughout the brain and focal reservoirs for productive HIV-1 replication.The neurotoxic events in the brain are caused by neurotoxins produced by these cells which are primed by HIV-1 and secondarily activated by factors such as immune stimuli or by T-cells trafficking through the nervous system.The primed and immune-activated brain macrophages/microglia secrete a variety of factors which affect neural and glial function and eventually lead to CNS inflammation.A pro-inflammatory cytokine response from blood-derived monocytes/macrophages, microglia, and astrocytes is amplified and leads finally to neurodegeneration.Immune neurotoxic factors may contribute to the breakdown of the BBB and affect the generation of chemokines, leading to transendothelial migration of monocytes into the brain perpetuating the inflammatory cascade.As a result of the neurotoxic activities of activated macrophages/microglia, astrocytes may suppress or increasemacrophages/microglia secretory functions and toxicity, depending on the astrocytic functional status.Cytolytic T-lymphocytes serve to eliminate infected cells, but are lost in late-stage HIV-1 disease, allowing the virus-induced, neurodegenerative response to continue unabated.Other factors include:viral proteinsCA^2+^ channelsNMDA receptorschemokines and cytokinesExpression of developmental proteins (Malik and Eugenin [@CR89]):Dickkopf homolog 1 (DKK1): upregulatedRho-associated, coiled-coil containing protein kinase 2 (ROCK2)---upregulatedLow density lipoprotein receptor-related protein-associated protein 1 (LRPAP1)---upregulatedLow density lipoprotein receptor-related protein 5-like (LRP5L)---downregulatedLow density lipoprotein-related protein 12 (LRP12)---upregulatedLow density lipoprotein receptor-related protein 8, apolipoprotein e receptor (LRP8)---downregulatedCatenin (cadherin-associated protein), alpha-like 1 (CTNNAL1)---upregulatedCatenin, beta-like 1 (CTNNBL1)---downregulatedCatenin (cadherin-associated protein), delta 1 (CTNND1)---downregulatedCatenin (cadherin-associated protein), alpha-like 1 (CTNNAL1)---upregulatedGlycogen synthase kinase 3 beta (GSK3B)---downregulatedWingless-type MMTV integration site family, member 10A (WNT10A)---downregulatedFor more details, see (Zayyad and Spudich [@CR158]; Singh [@CR126]; Ru and Tang [@CR115]; Rao et al. [@CR110]; Malik and Eugenin [@CR89]; Lamers et al. [@CR77]; Joseph et al. [@CR68]; Chen et al. [@CR29]; Carroll and Brew [@CR27]).

Interactions between the blood--brain barrier (BBB) and HIV (Hong and Banks [@CR60])

Mechanisms involving the BBB in HIV-infectionPassage of HIV cell-free virus across the BBBTranscytotic (mannose 6 phosphate receptor dependent)Paracellular (tight junction dissolution)Passage of HIV-1 proteins (gp120, Tat) across the BBBIncreased immune Ccll trafficking across the BBBActivated and infected T cellsActivated and infected monocytesTransport of cytokines across the BBBInduction of cytokine release from barrier cellsIncreased BBB leakinessBrain-to-blood efflux of antiviralsProtease inhibitors by P-glycoproteinAZT by organic ion transporterAltered BBB transporter expression and function (e.g., P-glycoprotein)Neurovascular unit effects

Therapeutic effects on involved pathways are illustrated in Table [26.15](#Tab15){ref-type="table"}.Table 26.15Therapy and effects on involved pathways (Sanchez and Kaul [@CR121]) reproduced with kind permission from MDPI open accessHIV or methamphetamine or HIV + MethHIV + cARTHIV + METH + cARTMicroglia activation↑↑↑Astrocytosis↑↑↑Alteration of neurotransmission↑↑HAND/HAD↑↓Oxidative stress↑↑↑Mitochondrial impairment↑ER stress↑Autophagy↓Neuronal dendrites↓↓Synapses↓↓Neuronal ATP↓↓↓Viral load↓

DNA-Virus: Cytomegalovirus Infection (CMV) {#Sec19}
==========================================

CytomegalovirusHerpesviruses, subfamily BetaherpesvirinaeLarge, enveloped viruses containing double-stranded DNA150 nm in diameter

Neuroradiology Findings {#Sec107}
-----------------------

General Imaging FeaturesPeriventricular white matter lesions, subependymal enhancementCalcifications in perinatal CMV CT Non-Contrast-Enhanced (Fig. [26.7a](#Fig7){ref-type="fig"})Periventricular hypodense lesionsPeriventricular hyperdense calcifications in perinatal CMV CT Contrast-EnhancedSubependymal enhancement possible MRI-T2/FLAIR (Fig. [26.7b, c](#Fig7){ref-type="fig"})Periventricular hyperintensities MRI-T1 (Fig. [26.7e](#Fig7){ref-type="fig"})Subependymal enhancement MRI-T1 Contrast-Enhanced (Fig. [26.7e](#Fig7){ref-type="fig"})Subependymal enhancement MRI-T2∗/SWI (Fig. [26.7f](#Fig7){ref-type="fig"})Periventricular hypointense calcifications in perinatal CMV

Neuropathology Findings {#Sec108}
-----------------------

Macroscopic FeaturesIn general, there are no gross-anatomical changes.Rarely, some small areas of necrosis are seen lining the ventricles, i.e., necrotizing ependymitis. Microscopic Features (Fig. [26.8a--j](#Fig8){ref-type="fig"})Microglial nodules are seen scattered throughout the nervous system.Large cells containing inclusion bodies are found within the microglial nodules.The microglial nodules located in the gray and white matter are usually not surrounded by a necrotic area.Along the periventricular spaces CMV-containing cells are found within the necrotic areas. Fig. 26.7Cytomegalovirus (CMV) infection: periventricular calcifications after perinatal CMV. CT non-contrast (**a**), T2 (**b**, **c**), T1 (**d**), T1 contrast (**e**), T2∗ (**f**) Fig. 26.8Cytomegalovirus (CMV) infection (**a**--**n**). Cells with inclusion bodies (**a**--**j**) (stain: H&E); cytomegalic cell with inclusion body (**k**--**n**) (stain: immunohistochemistry for CMV)

Progressive Multifocal Leukoencephalopathy (PML) {#Sec20}
================================================

John Cunningham Virus (JCV) is a member of the Polyomaviridae family

Polyomaviruses BK and JC are ubiquitous.Are 45 nm in diameter.Contain less than 5000 base pairs.Genomes of BK and JC are closely related.divided in early, late, and non-coding regionsJC virus etiological agent of the progressive multifocal leukoencephalopathy (PML)JC is an ubiquitous, neurotropic virus:50--90% of adult healthy individuals have been exposed to this virus.19--27% of those people shedding JCV in their urine.The seroprevalence increases with age but acquisition of this virus is not associated with a clinical syndrome.JC binds to sialylated carbohydrates and serotonin receptors to enter glial cells by endocytosis.DNA genome is uncoated and delivered to the nucleus.

Clinical Signs and Symptoms {#Sec110}
---------------------------

The pre-AIDS eraImpaired visionhomonymous hemianopsiaMotor weaknesshemiparesis or hemiplegiaChanges in mentation:personality changedifficulty with memoryemotional labilitydementiaAIDS-related PMLweakness (42%)speech abnormalities (40%)cognitive abnormalities (36%)gait abnormalities (29%)sensory loss (19%)visual impairment (19%)seizuresdiplopialimb incoordinationPML associated with monoclonal antibody therapycognitive disorders (48%)motor abnormalities (37%)language disturbances (31%)visual defects (26%)PML--IRIS immune reconstitution inflammatory syndromeParadoxical worsening of clinical or radiographic finding with recovery of the immune systemNew or increased neurologic deficitsIncrease in the number or size of lesions on neuroimagingContrast enhancement of brain lesionsBrain edemaConcurrent with diagnosis of PML

Neuroimaging Findings {#Sec112}
---------------------

General Imaging FeaturesConfluent subcortical white matter lesions, predominantly in parieto-occipital or frontal lobes, U-fibers involved CT Non-Contrast-Enhanced (Fig. [26.9a](#Fig9){ref-type="fig"})Multiple hypodensities in white matterNo mass effectIf bilateral often asymmetricNatalizumab-associated PML often monofocal CT Contrast-Enhanced (Fig. [26.9b](#Fig9){ref-type="fig"})Usually no enhancementEnhancement possible in HIV-associated PML and natalizumab-associated PML MRI-T2 (Fig. [26.9c](#Fig9){ref-type="fig"})Hyperintense MRI-FLAIR (Fig. [26.9d](#Fig9){ref-type="fig"})Hyperintense MRI-T1 (Fig. [26.9e](#Fig9){ref-type="fig"})Hypointense MRI-T1 Contrast-Enhanced (Fig. [26.9f](#Fig9){ref-type="fig"})Usually no enhancementEnhancement possible in HIV-associated PML and natalizumab-associated PML MRI-DWI (Fig. [26.9g](#Fig9){ref-type="fig"})Acute lesions hyperintense MRI-ADC (Fig. [26.9h](#Fig9){ref-type="fig"})Acute lesions hypointense

Neuropathology Findings {#Sec113}
-----------------------

Macroscopic Features (Fig. [26.10a--d](#Fig10){ref-type="fig"})Multiple areas of discoloration of the white matter.Sometimes, the white matter may appear softened and mottled. Microscopic Features (Fig. [26.10e--p](#Fig10){ref-type="fig"})Multiple foci of demyelination in the white matter consisting of loss of myelin sheaths.The oligodendrocytes are enlarged, amphophilic, and contain intranuclear inclusions.Enlarged, bizarre astrocytes. Fig. 26.9Progressive multifocal leukoencephalopathy (PML). CT non-contrast (**a**), CT contrast (**b**), T2 (**c**), FLAIR (**d**), T1 (**e**), T1 contrast (**f**), DWI (**g**), ADC (**h**) Fig. 26.10Progressive multifocal leukoencephalopathy: macroscopically, the white matter shows a moth-eaten appearance (**a**--**d**). The myelin of the left hemisphere is completely lost (stain: Woelcke's myelin stain) (**e**, **f**). Histology shows degeneration of myelin accompanied by the presence of reactive astrocytes, bizarre astrocytes/oligodendrocytes with large eccentric cytoplasm and lymphocytic infiltrates (**g**--**j**). Reactive astrogliosis (stain: GFAP) (**k**, **l**) and reactive microgliosis (stain: HLA-DRII) (**m**, **n**). Lymphocytes (stain: CD45) (**o**, **p**) are found in the perivascular spaces and within the brain tissue

Molecular Nauropathology {#Sec21}
------------------------

Development of PML (Berger and Khalili [@CR18])infection with JC virusestablishment of latent and/or persistent JC virus infectionrearrangement of JC virus into a neurotropic strain if initial infection has been with the archetype strainreactivation of the neurotropic JC virus strain from sites of viral persistence/latencyentry into the brainestablishment of productive infection of oligodendrocytesineffective immune system that prevents immunosurveillance from eliminating the infection

Drugs which cause PML are listed in Table [26.16](#Tab16){ref-type="table"}.Table 26.16Drug-induced cases of PML (Bauer et al. [@CR12]) reproduced with kind permission by Springer NatureMedicationTreatmentAzathioprineTransplantation/autoimmune diseaseCyclosporineTransplantationCyclophosphamideCancer/transplantation/autoimmune diseaseDimethylfumarateAutoimmune diseaseEfalizumabAutoimmune disease (psoriasis)FingolimodAutoimmune diseaseInfliximabAutoimmune diseaseLeflunomidAutoimmune diseaseMethotrexateCancer/autoimmune diseaseMycophenolateTransplantation/autoimmune diseaseNatalizumabAutoimmune diseaseRituximabCancer/autoimmune diseaseTacrolimusTransplantation

The differences between progressive multifocal leukoencephalopathy (PML), progressive multifocal leukoencephalopathy---immune reconstitution inflammatory syndrome (PML--IRIS) and multiple sclerosis (MS) with regard to anatomical, neuropathological, and MRI features are shown in Table [26.17](#Tab17){ref-type="table"}.Table 26.17Comparative anatomical, neuropathological, and MRI features of progressive multifocal leukoencephalopathy (PML), progressive multifocal leukoencephalopathy---immune reconstitution inflammatory syndrome (PML--IRIS) and multiple sclerosis (MS) (Bauer et al. [@CR12]) reproduced with kind permission by Springer NaturePMLPML--IRISMS*Anatomical features*• Lesions mostly reside in cerebral hemispheres but periventricular lesions are rare.• Lesions predominantly affect the deep and subcortical white matter and can expand into the cortical gray matter.• Intracortical lesions are present.• Spinal cord and optic nerves are spared.• Lesion distribution is similar to PML.• Lesions can be found in white and gray matter, but are often found in a periventricular position.• Unlike in PML, lesions can be found in spinal cord and optic nerves.*Neuropathological features*• Demyelinating lesions reveal oligodendrocytes with enlarged nucleus and cytoplasm. The nucleus may show inclusion bodies.• Oligodendrocytes are mostly found on the border of the lesion.• Subpial lesions are absent.• Remyelination is absent.• Within the demyelinated lesions, large (the so-called bizarre) astrocytes are found.• Lesions contain low to moderate numbers of T-cells.• few B-cells• few plasma cells• Activated microglial cells and macrophages are present in high numbers.• Like PML, lesions contain infected cells, especially on the border.• In small samples (biopsies) however, infected cells may be low in numbers or may be absent.• Subpial lesions are absent.• Remyelination is absent.• Like in PML, lesions contain bizarre astrocytes.• Lesions contain extremely high numbers of T-cells and B-cells.• Numbers of microglia and macrophages do not differ with PML.• Unlike in PML, lesions are perivenous and show finger-like extensions (i.e., Dawson fingers).• Subpial lesions are present and are specific for MS.• Lesions can show variable remyelination.• Lesions can show activated astrocytes and/or astrogliosis.• Extremely large bizarre astrocytes are absent.• Lesions contain moderate to high numbers of T-cells.• Low numbers of B-cell• Low numbers of plasma cells• Numbers of (foamy) macrophages do not differ from PML or PML--IRIS.*MRI features*• Usually larger than 3 cm• Lesions always start in subcortical regions, probably related to a high blood flow.• Borders are sharp towards the GM and ill-defined towards the WM.• In first scans of 28% of patients, lesions extend in deep GM.• 23--57% of (HIV-associated) cases have contrast-enhancing lesions.• T1 lesions are mostly hypointense.• Diffusion-weighted images are always hyperintense.• Punctate T2-hyperintense lesions can be found in the immediate vicinity of the main lesion.• Usually larger than 3 cm• Lesions always start in subcortical regions, probably related to a high blood flow.• Borders are sharp towards the GM and ill-defined towards the WM.• In first scans of 71% of patients, lesions extend in deep GM.• 86% of PML--IRIS cases have contrast-enhancing lesions.• T1 lesions may have hyperintense rims.• Diffusion-weighted images are always hyperintense.• Punctate T2-hyperintense lesions can be found in the immediate vicinity of the main lesion.• All MRI features seen in PML and/or PML--IRIS also can be seen in MS.• However, MS lesions usually are and stay smaller in size than in PML or PML--IRIS.• Homogeneous or open-ring enhancing lesions are present in MS but not observed in PML.

Prognostic factors of the evolution of progressive multifocal leukoencephalopathy have been described (Gheuens et al. [@CR49]) and include:Favorable factors:Detectable JCV-specific cellular immune response in blood or CSFRapid clearance of JCV from CSFCD4 count \>200 μL − 1 at onsetUnfavorable factors:Undetectable JCV-specific cellular immune response in blood or CSFMass effect on MRIPosterior fossa lesionsHigh JC viral load in CSFCD4 count \<200 μL − 1 at onset

Herpes Simplex Virus (HSV) Encephalitis {#Sec22}
=======================================

Herpesviruses areLarge, enveloped viruses.Contain double-stranded DNA.150 nm in diameter.DNA core surrounded by an icosadeltahedral capsid containing 162 capsomeres.Capsid is enclosed by a glycoprotein-containing envelope.Encode proteins that manipulate the host cell and immune response.DNA replication and capsid assembly occurs in the nucleus.Virus is released byExocytosisCell lysisThrough cell-to-cell bridgesCause lytic, persistent, latent, and immortalizing infections

Clinical Signs and Symptoms {#Sec114}
---------------------------

HeadacheNeck stiffnessDrowsinessComaDysphagiaHemiparesisFocal seizures

Neuroimaging Findings {#Sec115}
---------------------

General Imaging FeaturesInvolvement of limbic system and temporal lobeOften hemorrhages and enhancementOften bilateral, but asymmetric CT Non-Contrast-Enhanced (Fig. [26.11a](#Fig11){ref-type="fig"})Normal (early) to mild hypodense, swollen temporal lobes and insula CT Contrast-EnhancedPatchy enhancement possible MRI-T2/FLAIR (Fig. [26.11b--d](#Fig11){ref-type="fig"})Hyperintense, swollen white matter and cortex of affected areas.Hemorrhages may be hypointense. MRI-T1 (Fig. [26.11e](#Fig11){ref-type="fig"})Hypointense edemaLoss of gray-white matter differentiation MRI-T1 Contrast-Enhanced (Fig. [26.11f](#Fig11){ref-type="fig"})Diffuse enhancement MRI-T2∗/SWIHemorrhages hypointense MR-Diffusion Imaging (Fig [26.11g](#Fig11){ref-type="fig"})Often restricted diffusion MRI-ADC (Fig. [26.11h](#Fig11){ref-type="fig"})Often restricted diffusion

Nuclear Medicine Findings (Fig. [26.12](#Fig12){ref-type="fig"})Decreased FDG uptakeAfter recovery FDG uptake appears regular

Neuropathology Findings {#Sec1199}
-----------------------

Macroscopic Features (Fig. [26.13a, b](#Fig13){ref-type="fig"})CongestionHemorrhagic necrosis of theTemporal lobeInsulaCingulate gyrusPosterior orbitofrontal cortex Microscopic Features (Fig. [26.13c, d](#Fig13){ref-type="fig"})Acute phaseparenchymal inflammationlymphocytes and macrophages in the leptomeningesnecrotic cellsfoci of hemorrhagesperivascular and interstitial infiltrate of lymphocytesmicroglial nodulesneuronophagiaChronic phaseglial scar tissueclusters of lymphocytes

Molecular Neuropathology {#Sec116}
------------------------

PathogenesisPrimary mucocutaneous infectionmucocutaneous border of lips or oropharyngeal mucosaLatency in trigeminal ganglionby retrograde axonal transport along sensory fibers to the trigeminal ganglionfurther replicationlatent infection (latency-associated transcripts)Reactivation of virusanterograde transport to the skin or mucosedevelopment of cold soresreactivationspontaneouslymucocutaneous traumaultraviolet irradiationemotional stresspyrexiafluctuations in estrogen and progesterone concentrationsimmunosuppression

Treatment and Prognosis {#Sec2116}
-----------------------

OutcomeFatal outcome within a few days when untreatedTreatment Fig. 26.11Herpes encephalitis with characteristic involvement of right limbic system, temporal and basal frontal lobe, restricted diffusion and weak enhancement; CT non-contrast (**a**), T2 ax/cor (**b**, **c**), FLAIR (**d**), T1 (**e**), T1 contrast (**f**), DWI (**g**), ADC (**h**) Fig. 26.12Herpes encephalitis: decreased FDG uptake (left 3 rows) in a patient during the recovery phase of Herpes simplex encephalitis and regular FDG uptake after recovery (right 3 rows) Fig. 26.13Herpes encephalitis: macroscopically, necrosis is seen in both temporal lobes (arrow) (**a**, **b**). The virus is demonstrated by immunohistochemistry mainly in neurons (**c**, **d**)

Tick-Borne Encephalitis {#Sec23}
=======================

Tick-borne encephalitis (TBE) is an infection of the central nervous system (CNS) caused by tick-borne encephalitis virus (TBEV) and transmitted by ticks, with a variety of clinical manifestations (Table [26.18](#Tab18){ref-type="table"}). The incidence of TBE in Europe is increasing due to an extended season of the infection and the enlargement of endemic areas.Table 26.18Viruses causing tick-borne encephalitisVirusBrain region affectedMortalityMorbidityGeographic distributionEastern equine encephalitis50--75%90% of survivors have persistent neurologic disability.• Eastern and Gulf coast states of the USA.• Caribbean• South AmericaWestern equine encephalitis• Basal ganglia• Thalamus• Brain stem\<5%• Western and Midwestern USASt. Louis encephalitis• Midbrain• Thalamus\<5%25% of survivors have persistent neurologic disability.• The USA• Central America• South AmericaJapanese encephalitis• Thalamus• Substantia nigra• Brain stem• Spinal cordUp to 50%High percentage of survivors have persistent neurologic disability.• Southeast Asia• Bangladesh• PakistanWest Nile virus• Thalamus• Cerebellum• Substantia nigra• Pons• Medulla oblongata• Spinal cord3--15%50--75% of survivors have residual neurologic disability.• Africa• Eastern Europe• West Asia• Middle East• North AmericaTick-borne encephalitis1--10%Small percentage develop chronic encephalitis with intractable epilepsy and progressive paralysis (Russian spring-summer encephalitis).

Causative agents:TogaviridaeFlaviviridaeReoviridaeBunyaviridae

TBE is a caused by flavivirusWestern Europe subtype, tick vector: *Ixodes ricinus*Siberian subtype, tick vector: *Ixodes persulcatus*Far eastern subtype, tick vector: *Ixodes persulcatus*

Clinical Signs and Symptoms {#Sec401}
---------------------------

Meningitis typically manifests withHigh feverHeadacheNauseaVomitingEncephalitis can be manifested byImpaired consciousnessSomnolenceStuporComaMyelitisOther manifestations comprisePersonality changesBehavioral disordersConcentration and cognitive function disturbancesTongue fasciculations and tremor of extremitiesFocal or generalized seizuresDeliriumPsychosis

Epidemiology {#Sec9010}
------------

IncidenceHighly endemic areas (≥5 cases/100 000/year)

Neuroimaging Findings {#Sec8001}
---------------------

General Imaging FeaturesMRI and CT often normal, rarely lesions in thalamus, cerebellum, or basal ganglia CT Non-Contrast-EnhancedUsually normal MRI-T2/FLAIR (Fig. [26.14a, b](#Fig14){ref-type="fig"})Lesions hyperintense MRI-T1 (Fig. [26.14c](#Fig14){ref-type="fig"})Lesions hypointense MRI-T1 Contrast-Enhanced (Fig. [26.14d](#Fig14){ref-type="fig"})Meningeal or parenchymal enhancement possible MR-Diffusion Imaging (Fig. [26.14e](#Fig14){ref-type="fig"})Restricted diffusion possible MRI-ADC (Fig. [26.14f](#Fig14){ref-type="fig"})Restricted diffusion possible Nuclear Medicine Imaging Findings (Fig. [26.15](#Fig15){ref-type="fig"})decreased FDG uptake

Neuropathology Findings {#Sec123}
-----------------------

Macroscopic Featuresmoderate to sever congestion (Fig. [26.15](#Fig15){ref-type="fig"})petechial hemorrhages Microscopic Features (Fig. [26.16a--l](#Fig16){ref-type="fig"})lymphocytic infiltratesleptomeningealperivascularparenchymalmicroglial nodules and macrophagesfocal necrosis of white matter myelinated fibersthrombosed small vessels

Molecular Neuropathology {#Sec121}
------------------------

Virus enters the vector (mosquito or tick) while it is feeding on the blood of an infected host.Is transmitted to other hosts in the salivary secretions of the vector.Natural hosts are birds or small mammals (rodents).Humans are dead-end hosts.Virus replicates at the site of host inoculation.Spreads to regional lymph nodes and other lymphoreticular tissues.Disseminates hematogenously to systemic tissues (CNS).

Treatment and Prognosis {#Sec120}
-----------------------

TreatmentNo specific drug therapyCorticosteroidsTracheal intubation and respiratory support OutcomeComplete restitution to fatalPrevention:vaccination Fig. 26.14Tick-borne encephalitis with T2-hyperintensity and mild enhancement of thalami and basal ganglia. T2 (**a**), FLAIR (**b**), T1 (**c**), T1 contrast (**d**), DWI (**e**), ADC (**f**) Fig. 26.15Tick-borne encephalitis: totally decreased FDG uptake in cerebral cortex Fig. 26.16Tick-borne encephalitis: histological examination reveals perivascular lymphocytic infiltrates (**a**, **b**) and the presence of gliomesenchymal nodules (**c**, **d**) which may contain multinucleated giant cells (**e**, **f**). The perivascular infiltrates are mainly made up of CD3-positive T-lymphocytes (**g**) which are also homing in the surrounding brain tissue (**h**). Reactive astrogliosis (stain: GFAP) (**i**, **j**) and reactive microgliosis (stain: HLA-DRII) (**k**, **l**) might be moderate
